news Three new assays to test COVID-19 antivirals developed 30 April 2020 | By Victoria Rees (Drug Target Review) A series of three new assays to screen for drug compounds or proteins that combat the COVID-19 coronavirus has been developed.
news Antibodies developed from llama show promise in fighting COVID-19 30 April 2020 | By Victoria Rees (Drug Target Review) Engineering antibodies found in a llama, researchers have developed a potential COVID-19 therapy which they say can neutralise SARS-CoV-2.
article Developing respiratory therapeutics for prophylaxis and treatment 30 April 2020 | By Hannah Balfour (Drug Target Review) Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
news AI platform developed to rapidly identify treatment regimens for infections, including COVID-19 29 April 2020 | By Victoria Rees (Drug Target Review) A new AI tool has been created by researchers to identify the best treatment courses and doses for bacterial or viral infections, such as COVID-19.
news Multidrug nanoparticles developed for treatment of COVID-19 inflammation 28 April 2020 | By Victoria Rees (Drug Target Review) Multidrug nanoparticles for the targeted delivery of drugs could be used to combat inflammation in COVID-19 patients, say researchers.
news NIAID releases strategic plan, outlining COVID-19 research priorities 28 April 2020 | By Hannah Balfour (Drug Target Review) The US National Institute of Allergy and Infectious Diseases (NIAID) plan outlines four research priorities, including furthering understanding of SARS-CoV-2 viral transmission and pathogenesis and development of animal models.
article Cytokine storms: a major killer in patients with severe COVID-19 infection 27 April 2020 | By Professor Saad Shakir (Drug Safety Research Unit) Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
article Natural peptides versus COVID-19 25 April 2020 | By Oleg Kit (Interregional Academy of Personnel Management), Yuriy Kit (National Academy of Science of Ukraine) Peptides could serve as a potential platform for development of novel drugs for the treatment of the COVID-19 coronavirus.
news Fundamental molecular research underpins our ability to combat COVD-19, says article 23 April 2020 | By Hannah Balfour (Drug Target Review) Ali Shilatifard’s article explains how investment in institutes performing molecular research is essential, as it is the foundation for all attempts to combat COVID-19 and other future pandemics.
news Lead SARS-CoV-2 inhibitor compound identified by researchers to treat COVID-19 23 April 2020 | By Victoria Rees (Drug Target Review) Researchers have found a lead compound which they say inhibits SARS-CoV-2 viral replication and demonstrates good pharmacokinetic activity in vivo.
news Glycomimetics could prevent COVID-19 from infecting human cells 21 April 2020 | By Hannah Balfour (Drug Target Review) Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
news UK government funds 21 new research projects into COVID-19 20 April 2020 | By Victoria Rees (Drug Target Review) A total of 21 COVID-19 research projects have been granted funding by the UK government, including vaccine and therapeutic development.
news Cynomolgus macaques: a promising animal model of COVID-19 infection? 17 April 2020 | By Hannah Balfour (Drug Target Review) Researchers comparing the effects of SARS-CoV-2, SARS-CoV and MERS-CoV in cynomolgus macaques suggest they could be an effective animal model for testing COVID-19 therapeutics.
news Screening 10,000 compounds identifies six potential COVID-19 therapeutics 17 April 2020 | By Hannah Balfour (Drug Target Review) High-throughput screening of thousands of compounds has revealed several candidates, including lead compound ebselen, with the potential for treating COVID-19.
news Specialised proteins could halt cytokine storms in COVID-19 patients 17 April 2020 | By Victoria Rees (Drug Target Review) Researchers who developed modified proteins say this could be used in the fight against COVID-19, by tackling cytokine storms.
